The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe ...

Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, ...

David Risinger’s rating is based on the promising topline data from Eli Lilly’s Phase 3b ADapt trial, which showcased the effectiveness of Ebglyss (lebrikizumab) for patients with moderate-to ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

New results show Eli Lilly’s (LLY) Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results from the ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients with ...

Eli Lilly's EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from the Phase IIIb ADapt study.